Oncology Medical News about adjuvant therapy;pegylated interferon alpha-2 b;resected stage lll melanoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma group
Journal of Clinical Oncology, 06/22/09

Bottomley A et al. - Data demonstrate that pegylated IFN-α-2b (PEG-IFN-α-2b) leads to a significant and sustained improvement in recurrence-free survival (RFS). However, a negative effect on global health-related quality of life (HRQOL) and selected symptoms were observed when patients undergo this treatment.

Methods

Study examines the HRQOL effects of adjuvant PEG-IFN-α-2b vs observation in pts with stage III melanoma
1,256 pts; randomly assigned after full lymphadenectomy to receive either:
- Observation (n=629) or
- PEG-IFN-α-2b (n=627): induction 6 g/kg/wk for 8 wks then maintenance 3 g/kg/wk for 5 yrs
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 was used to assess HRQOL

Results

At 3.8 yrs of median f/u, for the primary end point, RFS risk was reduced by 18% in the PEG-IFN-α-2b arm
PEG-IFN-α-2b treatment arm showed decreased global HRQOL at mo 3 and yr 2
Many of the other scales showed significant differences between scores when comparing the 2 arms
From a clinical point of view, important differences were found for 5 scales:
- 2 functioning scales (social and role functioning) and
- 3 symptom scales (appetite loss, fatigue, and dyspnea)
  with the PEG-IFN-α-2b arm being most impaired

<< Previous
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab,...

Next >>
Phase III postoperative adjuvant radiotherapy after radical...